Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
May 07,2024
Technological Innovation, Authority Reaffirmed! Medicilon was awarded the "2023 Shanghai Science and Technology Little Giant Enterprise"
Recently, the Shanghai Science and Technology Commission officially issued the "Notice on the Announcement of the List of 2023 Shanghai Science and Technology Little Giants (Including Cultivation) Enterprises". Medicilon was recognized as one of the 2023 Shanghai Science and Technology Little Giants Company.
More
Technological Innovation, Authority Reaffirmed! Medicilon was awarded the "2023 Shanghai Science and Technology Little Giant Enterprise"
May 07,2024
World Cancer Day Focus: AACR Annual Meeting Leads Global New Cancer Drug Trends, Domestic Drugs Lead the Trend
At the AACR annual meeting, many top cancer research experts shared the latest scientific and medical research results. ​What is also eye-catching is that the Medicilon antibody drug conjugate (ADC) R&D service platform demonstrated its strong strength at this annual meeting.
More
World Cancer Day Focus: AACR Annual Meeting Leads Global New Cancer Drug Trends, Domestic Drugs Lead the Trend
May 07,2024
Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs
On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs.
More
Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs
Apr 10,2024
Medicilon (Chuansha) Inc. won the "Development Potential Award" of Chuansha New Town
Medicilon, relied on its outstanding performance and strong development momentum in the field of biopharmaceutical, won the "Development Potential Award" for the 2023 Chuansha New Town Economic Work Advanced Unit.
More
Medicilon (Chuansha) Inc. won the "Development Potential Award" of Chuansha New Town
Apr 10,2024
The 2024 Medicilon Innovative Drug Industry Ecological Collaboration Conference was a complete success
On March 18, the Medicilon Innovation Drug Industry Ecological Collaboration Conference was successfully held. At the conference, Medicilon starts of the globalization and the grand launch of two key technology service platforms.
More
The 2024 Medicilon Innovative Drug Industry Ecological Collaboration Conference was a complete success
Apr 10,2024
Medicilon once again ranked on the 2024 Shanghai Hard Core Technology Enterprises TOP100 List
Medicilon won the "2024 Shanghai Hard Core Technology Enterprises TOP100 List" with its hard-core technology and innovative technology service platform in the preclinical field of biopharmaceutical.
More
Medicilon once again ranked on the 2024 Shanghai Hard Core Technology Enterprises TOP100 List
Apr 10,2024
Medicilon and Innoforce Pharmaceuticals have reached a strategic collaboration to accelerate the innovative development of RNA, cell and gene therapy
On March 18, Medicilon and Innoforce Pharmaceuticals (Innoforce) reached a strategic collaboration, focusing on cutting-edge fields such as RNA, cell and gene therapy, and work together to open a new chapter in innovative drug research and development.
More
Medicilon and Innoforce Pharmaceuticals have reached a strategic collaboration to accelerate the innovative development of RNA, cell and gene therapy
Mar 19,2024
Medicilon Appoints Dr. Wenjie Li as Vice President of the CMC Unit to Expand our CRDMO Business
Medicilon announced the appointment of Dr. Wenjie Li as Vice President of the CMC Unit. With this appointment, Dr. Wenjie Li will continue to expand and strengthen Medicilon's services in the CRDMO field.
More
Medicilon Appoints Dr. Wenjie Li as Vice President of the CMC Unit to Expand our CRDMO Business
Mar 11,2024
Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout
Medicilon officially appoints Dr. Qingcong Lin as Executive Vice President and President of Medicilon USA Corp, a significant step to deepen its global and strategic layout.
More
Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout
Feb 28,2024
Medicilon 20th Anniversary - Keep pace with the times in innovation, thanks for having you
In 2024, Medicilon will celebrate its 20th anniversary. During the past 20 years, Medicilon has transformed into a leading one-stop biopharmaceutical preclinical R&D service CRO in China, and is moving forward with its goal of being a world-class CRO.
More
Medicilon 20th Anniversary - Keep pace with the times in innovation, thanks for having you
Feb 21,2024
Medicilon won the "Best Strategic Partner" award from NewDEL Biotech in 2023
Shanghai Medicilon Inc. (Medicilon) has recently won the "Best Partner Award" from Gluetacs Therapeutics and the "2003 Best Partner Award" from SicaGene.
More
Medicilon won the "Best Strategic Partner" award from NewDEL Biotech in 2023
Jan 30,2024
Medicilon was selected as the "2023 Shanghai Professional Technical Service Platform"
On January 18, the Science and Technology Commission of Shanghai Municipality released the 2023 Shanghai Professional Technical Service Platform construction project list. There are only 29 platforms in Shanghai on the list. Medicilon Preclinical Research (Shanghai) LLC, a subsidiary of Shanghai Medicilon Inc. (Medicilon), Nucleic Acid Drug R&D Service Platform was successfully selected!
More
Medicilon was selected as the "2023 Shanghai Professional Technical Service Platform"
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->